Health
Immunotherapy combination shrinks rare angiosarcoma tumors in 25% of patients – News-Medical.Net
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s Division of Cancer Diagnosis and Treatment,…
Reviewed by Emily Henderson, B.Sc.Nov 15 2020
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s (NCI) Division of Cancer Diagnosis and Treatment (DCTD), part of the National Institutes of Health, have shown that the immunotherapy combination of ipilimumab and nivolumab shrinks rare angiosarcoma tumors in 25 percent of all patients, with some having an even stronger response to the drug combination.
Results of the SWOG study, led…
-
General13 hours agoWondering about winter | The Spectator Australia
-
Noosa News22 hours agoOz Lotto’s $70 million jackpot won by Queensland syndicate – but not all of the winners know yet
-
Noosa News20 hours agoMan charged with murder after wife found dead in suspicious house fire near Toowoomba
-
Noosa News19 hours agoCameron Hunt, 45, charged with murder after body of his wife Louise Hunt found inside their Geham home just outside Toowoomba